GD Biosciences Announces PULS Cardiac Test Distribution Partnership With Cleveland HeartLab, Inc.

Exclusive Distribution Partnership with Cleveland HeartLab, Inc. will enhance access to the PULS Cardiac Test throughout the United States
(PR NewsChannel) / July 5, 2016 / IRVINE, Calif. 

GD Biosciences - PULS Cardiac TestIrvine, California-based Global Discovery Biosciences (GD Biosciences), a biotechnology company dedicated to research and development of innovative solutions to some of the biggest challenges in healthcare, announced that it will partner exclusively with Cleveland HeartLab, Inc. to distribute the PULS Cardiac Test to physicians in the United States. Formed in 2009 as a spin-off from the Cleveland Clinic, Cleveland HeartLab, Inc. offers its testing to thousands of leading clinicians focused on health and wellness as well as corporate wellness plans through its CAP accredited and CLIA-certified clinical lab, and shares Global Discovery Biosciences’ commitment to preventing heart disease.

Heart disease remains the leading cause of death and disability worldwide, but is 80% preventable with early detection and lifestyle modifications. Most patients present with no signs or symptoms before a fatal or debilitating heart attack. Nearly half of all heart attacks are silent according to a study published on May 16th, 2016 in the American Heart Association Journal Circulation. The ability to identify these individuals before they have a heart attack has high clinical value.

The PULS (Protein Unstable Lesion Signature) Cardiac Test is an affordable, non-invasive blood test that has the ability to find these individuals before they experience a heart attack. The PULS Cardiac Test quantifies endothelial damage, measures the body’s immune response to the damage, and predicts risk of an acute coronary syndrome (ACS). The PULS Cardiac Test incorporates the most significant predictive markers and risk factors to provide a powerful indication of coronary artery endothelial damage and a risk for potential ACS. Measured and validated against the current gold standards in cardiology, the PULS Cardiac Test is a potential game changer in uncovering asymptomatic patients at real risk of heart attacks who are missed by current conventional methods.

Already being used by select physicians in the U.S., United Kingdom, Canada, and countries with growing heart disease problems such as Indonesia, China, Middle East, and India,  the PULS Cardiac Test is a diagnostic and predictive blood test that detects the body’s immune response to early coronary artery endothelial damage, often in patients with no symptoms of heart disease (the Vulnerable Patient).  The immune response frequently causes formation of unstable cardiac lesions that are like blisters or pimples in the coronary artery wall. These lesions can become unstable and rupture, forming a blood clot. This process blocks blood flow to the heart muscle and is the most common cause of Heart attacks (75%).

“The PULS Cardiac Test is becoming a critical tool for physicians to identify apparently healthy patients with silent disease who are at risk of heart attack. We tend to focus too much on cholesterol and the structural defects in heart disease, and not enough on the functional defects,’” said Douglas S. Harrington, M.D., CEO of GD Biosciences. “Free radicals, including oxidized cholesterol, cause damage to the coronary arteries. The body has the ability to repair this damage. In order to do so, it receives a signal from the injury to activate the immune response and repair the damage. We detect the body’s immune response to this injury with the PULS Cardiac Test and predict the likelihood of a heart attack in a 5 year timeline. This allows physicians to implement potentially life-saving prevention plans and improve patient care.”

Jake Orville, CEO of Cleveland HeartLab, Inc. commented “Numerous studies have shown that 50% of heart attack victims have normal cholesterol levels. Recently, the American Heart Association’s “Get with the Guidelines” revealed that over 70% of patients hospitalized with a first Acute Coronary Syndrome (Heart Attack) event were well within guideline targets for lipids. Cleveland HeartLab is focused on providing breakthrough innovations to the market and the PULS Cardiac Test complements our industry leading menu of cardiac tests and enhances our ability to provide Doctors and patients with actionable results.”

About the PULS Cardiac Test

The PULS Cardiac Test is a simple blood test that uses breakthrough medical technology to identify individuals with active, yet undetected subclinical Coronary Heart Disease (CHD), who are at risk of experiencing a Heart Attack, and for whom early intervention can help. The test measures the body’s immune system response to detect early arterial damage leading to the formation of unstable cardiac lesions – the cause of 75% of all Heart Attacks.

About GD Biosciences

Global Discovery Biosciences (GD Biosciences) is a pioneer in the field of diagnostic medicine and focuses on turning academic discoveries into innovative clinical products for global clinical applications, Its CLIA-certified and GMP laboratory performs a menu of clinically effective tests targeting key health issues. Our goal is to equip physicians with the tools they need to transform health care – one patient at a time.

About Cleveland HeartLab

Cleveland HeartLab Inc. (CHL) is the premier cardiovascular disease (CVD) Management Company with a comprehensive array of propriety tests focused on improving the early identification of those with CVD risk. In addition to its industry leading approach to inflammation testing, CHL manages a robust R&D program to accelerate the clinical use of scientifically proven and medically relevant biomarkers. CHL’s biomarkers have been validated in more than 100 peer-review studies published in leading medical and scientific journals. Half of all patients who suffer from heart attack have normal cholesterol. With the goal of improving CVD risk assessment, CHL’s unique testing provides a more complete picture of CVD risk allowing clinicians to deploy personalized medical programs and interventions to reduce the overall risk of CVD, with a specific focus on reducing the risks of inflammation. In a 2015 Journal of Medical Economics study on the economic impact of CHL’s core inflammation tests, CHL’s CVD management protocol demonstrated the potential to avoid nearly 10% of heart attacks and strokes for patients of average health. The cost of care averted was estimated to exceed $187 million. CHL holds over 20 issued and 30 pending global patents and has been recognized for its innovation with the prestigious Nortech Innovation Award,The Ohio Venture of the Year Award  and the Edison Crystal Award for Excellence. CHL was also named an “Inc. 5,000” company in recognition of its innovation and growth. For more information about CHL visit us at For more information on CVD visit

For GDB:
Adam Farragut
PR Firm: The Publicity Agency
Email: Phone: 813-708-1220 x7778

For Cleveland HeartLab:
Bethany Hilt
Email: Phone: 330.338.6633

Direct link:

SOURCE:  GD Biosciences

This press release is distributed by PR NewsChannel. Your News. Everywhere.